Project Grant K99CA297000
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$113K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $194,013 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Sanford Research, a non-profit biomedical research organization. The grant supports the development of a genetically engineered mouse model to study rhabdomyosarcoma, an aggressive form of soft tissue cancer in children. Specifically, the project aims to create mouse models that replicate key features of human rhabdomyosarcoma, and to evaluate the Notch1 signaling...
The National Cancer Institute (NCI) awarded a $730,398 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports a 5-year research project investigating the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, which are a lethal complication of cancer. The project leverages the institute's collection of...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $459,000 in funding to the New York Institute of Technology (NYIT) from July 1, 2025 to June 30, 2028. The project aims to gain crucial insights into the role of microRNAs in regulating choroid plexus differentiation and tumorigenesis, with a focus on understanding the molecular mechanisms underlying choroid plexus carcinoma (CPC), an aggressive pediatric brain cancer. The research will...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to understand the mechanisms by which a gene essential for rhabdoid tumor viability regulates chromatin function. The $148,568 award to St. Jude Children's Research Hospital will fund a 2.5-year project starting on Dec 25, 2024. The research aims to elucidate how loss of the target protein disrupts the balance between the SWI/SNF chromatin remodeling complex and the polycomb...
This federal Project Grant award of $166,752.00 was provided by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, to The Washington University in Missouri. The award period runs from July 1, 2025 to June 30, 2027. The grant supports research to elucidate the roles of myeloid cells within the peritoneal cavity and peritoneum during colorectal cancer peritoneal metastasis. Key objectives include profiling immune cell changes in patient samples,...
The National Cancer Institute (NCI) awarded a $560,458 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Children's Mercy Hospital in Kansas City, Missouri. This 5-year grant, effective March 11, 2025, supports research to identify a strategy and novel compounds that efficiently induce cell death specifically in cancer cells deficient in the p53 tumor suppressor gene, known as "p53 synthetic lethality." The key objectives are to determine the requirement of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
The National Cancer Institute (NCI) awarded a $153,512 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to St. Jude Children's Research Hospital Inc. in Memphis, TN. The grant, with a project period from December 18, 2024 to April 30, 2026, will fund research to investigate the role of the protein Caspase-8 in cancer cells and the tumor microenvironment, and how it impacts anti-cancer immunity and CAR-T cell function. The research aims to understand how Caspase-8 influences...